Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
8376 | 1260 | 38.7 | 79% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
11 | 4 | NEUROSCIENCES//CLINICAL NEUROLOGY//NEUROL | 1112395 |
76 | 3 | NEUROSCIENCES//DOPAMINE//SEROTONIN | 81359 |
218 | 2 | SEROTONIN//5 HT1A RECEPTOR//5 HT2A RECEPTOR | 20633 |
8376 | 1 | 5 HT3 RECEPTOR//5 HT3 RECEPTOR ANTAGONIST//5 HT3 | 1260 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | 5 HT3 RECEPTOR | authKW | 2481170 | 20% | 40% | 255 |
2 | 5 HT3 RECEPTOR ANTAGONIST | authKW | 525988 | 7% | 26% | 84 |
3 | 5 HT3 | authKW | 458892 | 4% | 38% | 50 |
4 | 5 HT3 RECEPTOR AGONIST | authKW | 237473 | 1% | 70% | 14 |
5 | 5 HT3A | authKW | 205259 | 1% | 71% | 12 |
6 | LIGAND GATED ION CHANNEL | authKW | 202674 | 5% | 14% | 59 |
7 | H 3GRANISETRON | authKW | 193862 | 1% | 100% | 8 |
8 | 5 HT3B | authKW | 172320 | 1% | 89% | 8 |
9 | CONTINUOUS COCAINE | authKW | 172320 | 1% | 89% | 8 |
10 | ONDANSETRON | authKW | 171921 | 6% | 9% | 81 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 10457 | 53% | 0% | 667 |
2 | Neurosciences | 4794 | 37% | 0% | 462 |
3 | Chemistry, Medicinal | 1611 | 11% | 0% | 141 |
4 | Behavioral Sciences | 675 | 6% | 0% | 71 |
5 | Psychiatry | 497 | 8% | 0% | 103 |
6 | Biochemistry & Molecular Biology | 113 | 13% | 0% | 158 |
7 | Substance Abuse | 75 | 1% | 0% | 17 |
8 | Physiology | 60 | 3% | 0% | 43 |
9 | Chemistry, Organic | 37 | 4% | 0% | 53 |
10 | Biophysics | 7 | 2% | 0% | 26 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | FD 3 | 91332 | 1% | 54% | 7 |
2 | DRUG DISCOVERY MOL CHEM S | 48466 | 0% | 100% | 2 |
3 | DRUG DISCOVERY MOLEC DESIGN | 48466 | 0% | 100% | 2 |
4 | NEUROENDOCRINOL NEURODYNAM | 48466 | 0% | 100% | 2 |
5 | PHARMACOLCELLULAR MOL NEUROPHARMACOL | 48466 | 0% | 100% | 2 |
6 | KLIN ANASTHESIOL SPEZIELLE INTENS MED | 35629 | 0% | 29% | 5 |
7 | INTERDIPARTIMENTALE ANAL DETERMINAZIONI STR | 32309 | 0% | 67% | 2 |
8 | NCOUNTER CORE IL | 32309 | 0% | 67% | 2 |
9 | ADV LIGHT MICROSCOPY IL CELL BIOL CELL BIOPH | 24233 | 0% | 100% | 1 |
10 | AFFAIRS PROF | 24233 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EUROPEAN JOURNAL OF PHARMACOLOGY | 10939 | 9% | 0% | 113 |
2 | NEUROPHARMACOLOGY | 9887 | 5% | 1% | 62 |
3 | BRITISH JOURNAL OF PHARMACOLOGY | 6063 | 5% | 0% | 67 |
4 | PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR | 4437 | 4% | 0% | 48 |
5 | PSYCHOPHARMACOLOGY | 3825 | 3% | 0% | 44 |
6 | NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2267 | 2% | 0% | 24 |
7 | EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION | 2247 | 1% | 1% | 10 |
8 | JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 1969 | 3% | 0% | 42 |
9 | CNS DRUG REVIEWS | 1332 | 0% | 2% | 3 |
10 | RECEPTORS & CHANNELS | 1227 | 0% | 1% | 4 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | 5 HT3 RECEPTOR | 2481170 | 20% | 40% | 255 | Search 5+HT3+RECEPTOR | Search 5+HT3+RECEPTOR |
2 | 5 HT3 RECEPTOR ANTAGONIST | 525988 | 7% | 26% | 84 | Search 5+HT3+RECEPTOR+ANTAGONIST | Search 5+HT3+RECEPTOR+ANTAGONIST |
3 | 5 HT3 | 458892 | 4% | 38% | 50 | Search 5+HT3 | Search 5+HT3 |
4 | 5 HT3 RECEPTOR AGONIST | 237473 | 1% | 70% | 14 | Search 5+HT3+RECEPTOR+AGONIST | Search 5+HT3+RECEPTOR+AGONIST |
5 | 5 HT3A | 205259 | 1% | 71% | 12 | Search 5+HT3A | Search 5+HT3A |
6 | LIGAND GATED ION CHANNEL | 202674 | 5% | 14% | 59 | Search LIGAND+GATED+ION+CHANNEL | Search LIGAND+GATED+ION+CHANNEL |
7 | H 3GRANISETRON | 193862 | 1% | 100% | 8 | Search H+3GRANISETRON | Search H+3GRANISETRON |
8 | 5 HT3B | 172320 | 1% | 89% | 8 | Search 5+HT3B | Search 5+HT3B |
9 | CONTINUOUS COCAINE | 172320 | 1% | 89% | 8 | Search CONTINUOUS+COCAINE | Search CONTINUOUS+COCAINE |
10 | ONDANSETRON | 171921 | 6% | 9% | 81 | Search ONDANSETRON | Search ONDANSETRON |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | BARNES, NM , HALES, TG , LUMMIS, SCR , PETERS, JA , (2009) THE 5-HT3 RECEPTOR - THE RELATIONSHIP BETWEEN STRUCTURE AND FUNCTION.NEUROPHARMACOLOGY. VOL. 56. ISSUE 1. P. 273-284 | 130 | 71% | 92 |
2 | RAJKUMAR, R , MAHESH, R , (2010) THE AUSPICIOUS ROLE OF THE 5-HT3 RECEPTOR IN DEPRESSION: A PROBABLE NEURONAL TARGET?.JOURNAL OF PSYCHOPHARMACOLOGY. VOL. 24. ISSUE 4. P. 455 -469 | 117 | 64% | 37 |
3 | WALSTAB, J , RAPPOLD, G , NIESLER, B , (2010) 5-HT3 RECEPTORS: ROLE IN DISEASE AND TARGET OF DRUGS.PHARMACOLOGY & THERAPEUTICS. VOL. 128. ISSUE 1. P. 146-169 | 138 | 46% | 84 |
4 | LUMMIS, SCR , (2012) 5-HT3 RECEPTORS.JOURNAL OF BIOLOGICAL CHEMISTRY. VOL. 287. ISSUE 48. P. 40239-40245 | 62 | 79% | 34 |
5 | THOMPSON, AJ , LUMMIS, SCR , (2006) 5-HT3 RECEPTORS.CURRENT PHARMACEUTICAL DESIGN. VOL. 12. ISSUE 28. P. 3615-3630 | 87 | 60% | 94 |
6 | ENGLEMAN, EA , RODD, ZA , BELL, RL , MURPHY, JM , (2008) THE ROLE OF 5-HT3 RECEPTORS IN DRUG ABUSE AND AS A TARGET FOR PHARMACOTHERAPY.CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. VOL. 7. ISSUE 5. P. 454-467 | 105 | 48% | 39 |
7 | MACHU, TK , (2011) THERAPEUTICS OF 5-HT3 RECEPTOR ANTAGONISTS: CURRENT USES AND FUTURE DIRECTIONS.PHARMACOLOGY & THERAPEUTICS. VOL. 130. ISSUE 3. P. 338 -347 | 79 | 55% | 24 |
8 | GUPTA, D , PRABHAKAR, V , RADHAKRISHNAN, M , (2016) 5HT(3) RECEPTORS: TARGET FOR NEW ANTIDEPRESSANT DRUGS.NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. VOL. 64. ISSUE . P. 311 -325 | 88 | 44% | 0 |
9 | GREENSHAW, AJ , SILVERSTONE, PH , (1997) THE NON-ANTIEMETIC USES OF SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS - CLINICAL PHARMACOLOGY AND THERAPEUTIC APPLICATIONS.DRUGS. VOL. 53. ISSUE 1. P. 20-39 | 96 | 59% | 75 |
10 | REEVES, DC , LUMMIS, SCR , (2002) THE MOLECULAR BASIS OF THE STRUCTURE AND FUNCTION OF THE 5-HT3 RECEPTOR: A MODEL LIGAND-GATED ION CHANNEL (REVIEW).MOLECULAR MEMBRANE BIOLOGY. VOL. 19. ISSUE 1. P. 11 -26 | 86 | 49% | 134 |
Classes with closest relation at Level 1 |